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Abstract
Background—Patients hospitalized with acute heart failure may experience worsening 
symptoms requiring escalation of therapy. In-hospital worsening heart failure is associated with 
worse in-hospital and postdischarge outcomes, but associations between the timing of worsening 
heart failure and outcomes is unknown.
Methods—Using data from a large clinical registry linked to Medicare claims, we examined 
characteristics, outcomes, and costs of patients hospitalized for acute heart failure. We defined in-
hospital worsening heart failure by the use of inotropes or intravenous vasodilators, or initiation of 
mechanical circulatory support, hemodialysis, or ventilation. The study groups were early 
worsening heart failure (n = 1990), late worsening heart failure (n = 4223), complicated 
presentation (n = 15,361), and uncomplicated hospital course (n = 41,334).
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Results—Among 62,908 patients, those with late in-hospital worsening heart failure had higher 
in-hospital and postdischarge mortality than patients with early worsening heart failure or 
complicated presentation. Those with early or late worsening heart failure had more frequent all-
cause and heart failure readmissions at 30 days and 1 year, with resultant higher costs, compared 
with patients with an uncomplicated hospital course.
Conclusion—Although late worsening heart failure was associated with the highest mortality, 
both early and late worsening heart failure were associated with more frequent readmissions and 
higher health care costs compared to uncomplicated hospital course. Prevention of worsening 
heart failure may be an important focus in the care of hospitalized patients with acute heart failure.
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Disease Progression; Heart Failure; Hospitalization; Outcome Assessment (Health Care)
Introduction
Acute heart failure is a costly public health problem that results in more than 1 million 
hospitalizations annually in the United States.1 More patients 65 years and older are 
hospitalized for a primary diagnosis of heart failure than for any other condition.2 Some 
patients admitted with acute heart failure will experience a worsening of their condition 
during hospitalization. Worsening heart failure is defined as persistent or worsening 
symptoms requiring escalation of therapy.3-7 In-hospital worsening heart failure is 
associated with poorer in-hospital and postdischarge outcomes, including mortality, 
readmission, and higher costs.8 Outcomes are similar for patients who experience worsening 
heart failure in the first few days of hospitalization or later in the hospitalization.9 However, 
it is unknown whether there is a difference in outcomes and health care expenditures for 
patients who experience in-hospital worsening heart failure very early in the hospitalization 
(ie, during the first day) or later in the hospital course.
We sought to describe the characteristics of patients hospitalized for heart failure by the 
presence and timing of in-hospital worsening heart failure and examine associations between 
timing of worsening heart failure and mortality, readmission, and health care costs.
Methods
Data Sources
The Acute Decompensated Heart Failure National Registry (ADHERE) was a multicenter 
registry of patients hospitalized with acute heart failure in the United States.10 All adult 
patients hospitalized with new-onset or decompensated heart failure were eligible for 
inclusion in the registry.10 Each participating institution had institutional review board 
approval for participation in the registry. More than 185,000 patients from more than 300 
medical centers were enrolled between January 2001 and March 2006. Data were collected 
via retrospective chart review.
We obtained Medicare fee-for-service standard analytic claim files from the Centers for 
Medicare & Medicaid Services (CMS). Medicare claims contain information about inpatient 
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and outpatient services rendered and procedures performed and associated payment 
information. In addition, Medicare denominator files contain information about patient 
demographic characteristics, including information about eligibility and enrollment and 
death.
We linked the Medicare data and the registry data using a previously described method.11 
The institutional review board of the Duke University Health System approved the study.
Study Population
The study population consisted of Medicare fee-for-service beneficiaries 65 years or older 
who had a hospitalization recorded in the ADHERE registry between January 1, 2001, and 
December 31, 2004. Registry data after 2005 did not include information about the timing of 
inotrope administration and were not included in this study. We required that patients be 
enrolled in fee-for-service Medicare for at least 6 months before the index hospitalization. 
We excluded patients with elective admissions. We excluded patients who died in the 
hospital, left against medical advice, or were discharged or transferred to another short-term 
hospital or hospice from the measurement of 30-day and 1-year outcomes.12 The ADHERE 
registry collected information on individual hospital admissions, not individual patients, 
some patients had multiple enrollments in the registry. For this analysis, we selected the first 
admission in the registry for each patient.
Study Groups
Consistent with previously published studies, we defined in-hospital worsening heart failure 
on the basis of the use of intravenous inotropes or vasodilators; mechanical support 
including ventilator, dialysis, intra-aortic balloon pump, or left ventricular assist device; or 
an intensive care unit (ICU) stay during the index hospitalization.8 We assigned patients to 1 
of 4 comparison groups: early in-hospital worsening heart failure, late in-hospital worsening 
heart failure, complicated presentation, and uncomplicated hospital course. To highlight 
decompensation that occurs early in the hospital course, we categorized worsening heart 
failure by whether it occurred during the first hospital day or after the first hospital day. 
“Early inhospital worsening heart failure” occurred during day 1 of the hospitalization (ie, 
12 to 24 hours after presentation). “Late in-hospital worsening heart failure” occurred after 
the first day of the hospitalization. As in previous analyses, we classified patients who met 
the worsening heart failure criteria during the first 12 hours after presentation as having a 
complicated presentation, and classified patients who did not meet the worsening heart 
failure criteria during the hospitalization as having an uncomplicated hospital course.8 We 
used the earliest time point recorded or retrievable in the medical record to determine the 
baseline time point. We excluded patients who were transferred to an ICU but for whom the 
timing of transfer was not available.
Outcomes
Postdischarge outcomes of interest were all-cause mortality, all-cause readmission, 
readmission for heart failure, days alive and out of the hospital, and Medicare payments. We 
summarized these outcomes at 30 days and 1 year after discharge. We excluded patients 
from calculations of all postdischarge outcomes if they died in the hospital, left against 
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medical advice, or were transferred to another short-term hospital or hospice. Moreover, we 
excluded patients who enrolled in Medicare managed care during the follow-up period from 
calculations of the payment outcomes and of days alive and out of the hospital. We also 
measured all-cause mortality, length of stay, and Medicare payments associated with the 
index hospitalization.
We obtained information about all outcomes from the Medicare data. Death dates were 
available in the Medicare denominator files. Readmissions were identified from subsequent 
inpatient claims. Heart failure readmissions were identified by claims having a primary 
diagnosis of heart failure (International Classification of Diseases, Ninth Revision, Clinical 
Modification diagnosis code 428.×, 402.×1, 404.×1, or 404×3). Days alive and out of the 
hospital were calculated based on mortality and readmission dates identified above. 
Medicare payments were obtained from Medicare inpatient, outpatient, and professional 
claims. Payment information was adjusted for inflation using the Consumer Price Index 
medical care component and reported in 2010 US dollars.
Patient Characteristics
Patient characteristics were ascertained from ADHERE registry documentation, including 
demographic characteristics, medical history, findings from the initial evaluation, vital signs, 
laboratory test results, admission and discharge medications, and the year of the index 
hospitalization.
Statistical Analysis
We describe the baseline characteristics of the study population using frequencies and 
percentages for categorical variables and means with SDs or medians with interquartile 
ranges for continuous variables. We tested for differences between groups using χ2 tests for 
categorical variables and Kruskal-Wallis test for continuous variables.
We present the observed outcomes by study group. We summarize in-hospital mortality 
using frequencies and percentages, and we used χ2 tests to assess differences between 
groups. We summarize length of stay, days alive and out of the hospital, and Medicare 
payments using means with SDs or medians with interquartile ranges, and we used Kruskal-
Wallis tests to assess differences between groups. Calculations of the incidence of 
postdischarge mortality were based on Kaplan-Meier estimates, and we used log-rank tests 
to assess differences between groups. For both readmission outcomes, we estimated 
incidence using the cumulative incidence function, which accounts for the competing risk of 
mortality, and we assessed differences between groups using Gray tests.
We estimated unadjusted and adjusted hazard ratios (HRs) for all pairwise study group 
comparisons for all-cause mortality, all-cause readmission, and heart failure readmission at 
30 days and 1 year using Cox proportional hazards models. We used robust standard errors 
to account for clustering of patients within hospitals. We used linear mixed models to 
estimate the unadjusted and adjusted differences between the groups in the number of days 
alive and out of the hospital. We estimated unadjusted and adjusted cost ratios for average 
postdischarge Medicare payments between the groups using generalized linear mixed 
models with a log link and a Poisson error distribution that allowed for overdispersion. In 
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the mixed models, we allowed for hospital-level random intercepts to account for clustering 
of patients within hospitals. All unadjusted models included only the study group indicators. 
Consistent with previous studies, the adjusted models also controlled for patient baseline 
demographic characteristics, medical history, findings from the initial evaluation, vital signs, 
laboratory test results, and medications.8,13
Because of the number of outcomes in the study, we used α = .01 to establish statistical 
significance and we report 99% CIs. We used SAS version 9.3 (SAS Institute Inc, Cary, 
North Carolina) for all analyses.
Results
Table 1 shows the baseline characteristics of the study population. The study population 
included 62,908 patients, of whom 1990 (3.2%) had early in-hospital worsening heart 
failure, 4223 (6.7%) had late in-hospital worsening heart failure, 15,361 (24.4%) had a 
complicated presentation, and 41,334 (65.7%) had an uncomplicated hospital course. A 
small percentage of patients (n = 819 [1.3%]) may have experienced in-hospital worsening 
heart failure, as indicated only by a transfer to the ICU during the hospitalization, but were 
not included in the analysis because we did not have information about the timing of the 
transfers.
Table 2 shows the care received by patients during the index hospitalization. Patients with 
early in-hospital worsening heart failure were least likely to receive diuretics but most likely 
to receive dialysis, whereas patients with late in-hospital worsening heart failure were most 
likely to receive inotropes and mechanical ventilation. Patients with a complicated 
presentation were most likely to have an ICU stay during the index hospitalization but had 
the lowest rates of inotropes, dialysis, and mechanical circulatory support.
Table 3 shows the observed outcomes by study group. Patients with late in-hospital 
worsening heart failure had the longest length of stay (mean, 11.4 days) and highest index 
hospitalization costs, followed by patients with early in-hospital worsening heart failure 
(mean length of stay, 7.2 days). Patients with a complicated presentation or an 
uncomplicated hospital course had shorter hospital stays (mean, 6.3 and 4.8 days, 
respectively). Mortality rates were highest among patients with late in-hospital worsening 
heart failure—14.9% during the index hospitalization, 21.5% at 30 days, and at 52.2% at 1 
year. All-cause readmission rates at 30 days and 1 year were highest among patients with 
early in-hospital worsening heart failure (30.4% and 73.7%, respectively), compared with 
patients with late in-hospital worsening heart failure (28.7% and 69.5%, respectively), 
complicated presentation group (12.9% and 39.7%, respectively), and uncomplicated 
hospital course group (7.3% and 32.7%, respectively). The main determinant of 
postdischarge Medicare payments is readmission; thus, patients who experience early in-
hospital worsening heart failure had the highest postdischarge Medicare payments. Figure 1 
shows the Kaplan-Meier estimates of all-cause mortality, all-cause readmission, and heart 
failure readmission among patients with early and late in-hospital worsening heart failure.
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Table 4 shows the unadjusted and adjusted associations between study group and outcomes. 
Compared with late in-hospital worsening heart failure, early in-hospital worsening heart 
failure was associated with lower mortality at 30 days (adjusted HR, 0.69; 99% CI, 
0.57-0.83) and 1 year (adjusted HR, 0.81; 99% CI, 0.73-0.90). However, both groups had 
similar rates of all-cause and heart failure readmission. Although both groups had similar 
postdischarge Medicare payments at 30 days (adjusted cost ratio, 1.01; 99% CI, 0.86-1.17), 
early in-hospital worsening heart failure was associated with higher Medicare payments at 1 
year (adjusted cost ratio, 1.12; 99% CI, 1.03-1.21).
Patients in the early in-hospital worsening heart failure and complicated presentation groups 
had similar mortality at 30 days (adjusted HR, 1.00; 99% CI, 0.85-1.19) and 1 year (adjusted 
HR, 1.06; 99% CI, 0.96-1.18) and similar rates of all-cause and heart failure readmission. 
However, compared with complicated presentation, early in-hospital worsening heart failure 
was associated with higher postdischarge Medicare payments at 1 year (adjusted cost ratio, 
1.09; 99% CI, 1.02-1.17).
For all associations, uncomplicated presentation had more favorable outcomes than early or 
late in-hospital worsening heart failure (Supplemental Table).
Discussion
Using data from a large clinical registry of patients with acute heart failure in the United 
States, we examined associations between the timing of in-hospital worsening heart failure 
and patient outcomes. Patients with early and late in-hospital worsening heart failure had 
similar rates of comorbid conditions, with the exception that patients with early in-hospital 
worsening heart failure had more renal insufficiency. Patients with a complicated 
presentation or with inhospital worsening heart failure had more comorbid conditions, 
higher disease burden, and worse outcomes than patients with an uncomplicated hospital 
course. Patients with late in-hospital worsening heart failure had the longest and most costly 
hospitalizations and the highest rates of in-hospital and postdischarge mortality. Whereas 
late worsening heart failure was associated with higher mortality than early worsening heart 
failure, rates of all-cause and heart failure readmission were similar between the groups. 
Patients with a complicated presentation had the highest rates of ICU stay, but the stays 
were shorter than for those with worsening heart failure. Outcomes of patients with 
complicated presentation and early worsening heart failure were similar with respect to 
mortality and readmissions. However, at 1 year, patients with complicated presentation 
spent an average of 20 more days alive and out of the hospital that those with early in-
hospital worsening heart failure.
Our findings are consistent with previous clinical trials and registry studies, which found 
that in-hospital worsening heart failure is associated with longer hospitalizations, more 
frequent readmissions, and higher mortality.8,14-19 Although many of these studies used 
slightly different definitions of worsening heart failure, the overall message remains 
consistent. Our findings differ from previous studies that showed that outcomes did not 
differ according to whether worsening heart failure occurred before or after the fourth 
hospital day.9,18 To our knowledge, our study is the first to examine whether worsening 
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heart failure in the first 24 hours differs from worsening heart failure later in the 
hospitalization. We selected this time point was on the basis of clinical relevance, because 
the first hospital day is often when the patient either responds to the initial therapy or 
worsens. We found that outcomes do vary by this cut point. Early in-hospital worsening 
heart failure is associated with more hospital readmissions and higher health care costs, 
whereas late in-hospital worsening heart failure is associated with longer hospitalizations 
and higher in-hospital and postdischarge mortality.
Our results have important implications for the care of patients with acute heart failure. 
Treatment strategies that reduce in-hospital worsening heart failure may improve in-hospital 
and postdischarge outcomes and reduce health care expenditures. Our data suggest that 
patients with a complicated presentation, compared with those who experience worsening 
heart failure, differ in important ways. The complicated presentation group and the early 
worsening heart failure group were similar in terms of baseline characteristics and 
presentation but received different inhospital care and had different outcomes. We defined 
early in-hospital worsening heart failure to capture patients who were stable at the time of 
admission and experience decompensation during the first day of hospitalization. However, 
our findings show that the groups did not differ at baseline but diverged shortly thereafter, 
with the complicated presentation group receiving more aggressive therapy initially. The 
consequences of this variation in treatment were that patients with early in-hospital 
worsening heart failure spent an average of 20 fewer days alive and out of the hospital than 
those with a complicated presentation. This finding suggests that prompt identification and 
management for the prevention of early worsening heart failure may lead to better outcomes. 
These findings highlight the importance of early recognition and aggressive management of 
acute heart failure in the emergency department and by admitting physicians.
Different factors may account for the timing of in-hospital worsening heart failure. Patients 
with complicated presentation were those whose clinical instability was recognized early 
and treated appropriately. Patients with early in-hospital worsening heart failure, while 
similar at baseline to patients with complicated presentation, were treated less aggressively 
on arrival. This finding suggests that early in-hospital worsening heart failure may be driven 
by initial misdiagnosis, inadequate initial therapy, ineffective therapeutic response, or 
improper level of care decisions, again highlighting the need for the emergency department 
and admitting providers to promptly identify and aggressively treat appropriately upon 
presentation. Patients with late in-hospital worsening heart failure were those who did not 
respond to standard therapies or whose worsening status was not recognized until later in the 
hospital course, resulting in longer length of stay and increased risk for complications and 
poor outcomes.
Our study has several limitations. The study population included only patients 65 years and 
older enrolled in the ADHERE registry with Medicare data. The results may not be 
generalizable to other groups of patients with acute heart failure, though a previous study 
suggests that patients in the ADHERE registry are representative of the Medicare fee-for-
service heart failure population.12 Associations with outcomes may be influenced by 
residual measured and unmeasured confounders. There are limitations related to the 
definitions of early and late inhospital worsening heart failure. Our definitions of timing 
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were selected on the basis of clinical experience rather than on previous studies. To 
highlight the important difference between patients who have adequate response vs 
inadequate response to early in-hospital therapy, we defined early in-hospital worsening 
heart failure as occurring on the first hospital day and late inhospital worsening heart failure 
as occurring after the first hospital day. Data constraints also limited our study in several 
ways. First, although the decision to escalate care was based purely on the clinical judgment 
of the provider, we did not have information regarding the reason for the escalation of care. 
However, in this registry of acute decompensated heart failure, we considered this escalation 
to be due to worsening heart failure. The definition of what constitutes in-hospital worsening 
heart failure in ADHERE was different than the definition used in other studies, including 
RELAX-AHF. We used a 12-hour window for initiation of inotropes or vasodilators to 
mitigate the risk of misclassifying patients who had a complicated presentation.7, 19 Second, 
we were unable to include the group of patients with in-hospital worsening heart failure 
indicated only by transfer to an ICU during the hospitalization, because we did not have 
information about the timing of ICU transfers. Third, we were unable to incorporate 
information about initiation of ultrafiltration or up-titration of inotropes, vasodilators, or 
diuretics; or hourly timing of mechanical ventilation. These are variables that have been 
used in other studies to define worsening heart failure. Although all studies use the concept 
of worsening clinical course requiring escalation of therapy, there is no consensus about the 
variables that constitute escalation of therapy. Our definition of worsening heart failure was 
restricted because of the lack of these variables in our data set. Despite this limitation, our 
data set provides a unique opportunity to examine worsening heart failure in a real-world, 
older heart failure population. As a result of these limitations, we were unable to analyze 
data regarding response or lack of response to initial therapy, further complicating the 
distinction between complicated presentation and early in-hospital worsening heart failure.
In conclusion, in-hospital worsening heart failure can occur at varying times during the 
hospital course, either on presentation, early in the hospitalization, or late in the 
hospitalization. Although late in-hospital worsening heart failure was associated with higher 
mortality, both early and late in-hospital worsening heart failure were associated with more 
frequent readmissions and higher health care costs. Prevention of both early and late in-
hospital worsening heart failure should be an important focus for payers and providers in the 
care of hospitalized patients with acute heart failure.
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Figure. 
Kaplan-Meier Estimates of All-Cause Mortality, All-Cause Readmission, and Heart Failure 
Readmission Among Patients With Early or Late In-Hospital Worsening Heart Failure
Panel A shows the Kaplan-Meier estimates of all-cause mortality at 1 year after admission 
from the index hospitalization for patients with early in-hospital worsening heart failure and 
late in-hospital worsening heart failure (P < .001).
Panel B shows the Kaplan-Meier estimates of all-cause readmission at 1 year after discharge 
from the index hospitalization for patients with early in-hospital worsening heart failure and 
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late in-hospital worsening heart failure (P = .03 for the unadjusted analysis; P = .60 for the 
adjusted analysis).
Panel C shows the Kaplan-Meier estimates for heart failure readmission at 1 year after 
discharge from the index hospitalization for patients with early in-hospital worsening heart 
failure and late in-hospital worsening heart failure (P = .54 for the unadjusted analysis; P = .
30 for the adjusted analysis).
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